by Karp, Nolan S.; Salibian, Ara A.
Plastic and
Reconstructive Surgery: March 2021 -
Volume 147 - Issue 3 - p 580-584
Prepectoral breast reconstruction has minimized morbidity
and dynamic deformities associated with submuscular implant-based breast
reconstruction. However, reliance on implant coverage with acellular dermal
matrix in immediate implant reconstruction remains limited by high material costs.
The authors describe a technique in which anterior implant coverage in
prepectoral reconstruction is split into acellular dermal matrix
inferolaterally and synthetic, absorbable mesh superiorly. Use of acellular
dermal matrix inferiorly provides coverage and reinforces the inframammary
fold, whereas the absorbable mesh is trimmed and sutured to the acellular
dermal matrix at the appropriate tension to support the implant and relieve
pressure on mastectomy flaps. A retrospective review was performed on all
consecutive prepectoral one-stage breast reconstructions using this technique
at a single institution. Patient demographics, mastectomy and reconstruction
characteristics, reconstructive outcomes, and cost of support materials were
queried and analyzed. Eleven patients (21 breasts) underwent prepectoral
immediate implant reconstruction with Vicryl and acellular dermal matrix
anterior coverage. Average mastectomy weight was 775.8 g. Smooth, round
cohesive implants were used in all cases and average implant size was 514.5 ml.
Overall complication rates were low and included one minor infection (4.8
percent) and one case of minor mastectomy flap and partial nipple necrosis each
(4.8 percent). Calculated cost savings of Vicryl and acellular dermal matrix
anterior coverage was up to $3415 in unilateral and $6830 in bilateral cases.
Prepectoral breast reconstruction using acellular dermal matrix inferiorly and
Vicryl mesh superiorly is a safe technique that decreases material costs
associated with support materials and allows the surgeon to precisely control
the implant pocket and position. CLINICAL QUESTION/LEVEL OF EVIDENCE:
Therapeutic, IV.